Abstract 386P
Background
Wnt/β-catenin pathway is closely related to the development and progression of laryngeal squamous cell carcinoma (LSCC). Loss or reduction of ubiquitination and degradation of β-catenin in cytoplasm result in its accumulation in the nucleus and over-activation of the Wnt/β-catenin pathway. Folate receptor 1 (FRα) is overexpressed in numerous epithelial malignancies. However, the effect of FRα on Wnt/β-catenin pathway and its role in LSCC remains unclear.
Methods
Real-time RT-PCR, Western blot and immunohistochemistry(IHC) detects the mRNA and protein level of FRα in 30 cases of laryngeal squamous cell carcinoma (LSCC) tissues and adjacent normal tissues; Flag-FRα and Si# FRα plasmids were constructed and transfected to establish high FRα expression and low FRα expression cells; EdU assay, colony formation, scratch assay and transwell assay were performed to detect the of proliferation, colony formation, migration and invasion ability of cells; SiRNA#β-catenin was used to block Wnt/β-catenin signal and detected the ability of proliferation, colony formation, migration and invasion; confocal laser detects the subcellular distribution of β-catenin; SgRNA#EGFR was used to silence EGFR signal ; co-immunoprecipitation detects the ubiquitination level of β-catenin.
Results
Q-RT-PCR, WB and IHC showed that the mRNA and protein level of FRα in laryngeal carcinoma tissues was significantly higher than adjacent tissues, and the difference was statistically significant (P<0.01). Compared with FRα low expression (TU177/Flag and TU212/Si-FRα) cells, the proliferation, colony formation, migration and invasion abilities of FRα high expression (TU177/Flag-FRα and TU212/Si-NC) cells were enhanced; SiRNA#β-catenin inhibited FRα -induced cell proliferation, colony formation and migration. Confocal laser results showed that the nuclear accumulation of β-catenin was increased in FRα high expression cells. SgRNA#EGFR inhibited FRα -induced nuclear translocation of β-catenin. Co-immunoprecipitation results displayed that the ubiquitination of β-catenin was decreased in FRα high expression cells.
Conclusions
FOLR1 stabilized β-catenin promotes laryngeal carcinoma progression through EGFR signa.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
H.Tuo.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract